Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies

Pathology

Volumn 41, Issue 2, 2009, Pages 140-148

  Klebe, Sonja ^a   Nurminen, Markku ^b,c   Leigh, James ^d   Henderson, Douglas W ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibody; Calretinin; Metastatic adenocarcinoma; Panel; Pleural malignant mesothelioma; Tree regression analysis

Indexed keywords

BIOLOGICAL MARKER; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; WT1 PROTEIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLEURA MESOTHELIOMA; PREDICTION; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 61649085257     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802579250     Document Type: Article

References (62)

1. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17.
2. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001; 25: 43-50.
3. Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 2006; 119: 1303-11.
4. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006; 49: 561-8.
5. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval [see comments]. Am J Surg Pathol 1997; 21: 1409-19.
6. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007; 57: 190-9.
7. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 514-23.
8. Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999; 30: 313-23.
9. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48: 223-32.
10. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27: 1031-1051.
11. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129: 1407-14.
12. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007; 38: 1-16.
13. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001; 32: 529-36.
14. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 1994; 102: 255-64.
15. Battifora H, McCaughey WTE. Tumors of the Serosal Membranes. Atlas of Tumor Pathology, 3rd Series, Fascicle 15. Washington DC: Armed Forces Institute of Pathology, 1995.
16. Henderson DW, Shilkin KB, Langlois SL, Whitaker D. Malignant Mesothelioma. New York: Hemisphere, 1992; 412.
17. Churg A, Cagle PT, Roggli VL. Tumors of the Serosal Membranes. Washington DC: American Registry of Pathology/Armed Forces Institute of Pathology, 2006.
18. Sporn TA, Roggli VL. Mesothelioma. New York: Springer, 2004; 104-68.
19. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. Lyon: IARC, 2004; 128-36.
20. Galateau-Sallé F, Brambilla E, Cagle PT, et al. Pathology of Malignant Mesothelioma. London: Springer, 2006.
21. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, CA: Wadswoth & Brooks, 1984.
22. Nurminen M. Prognostic models for delayed onset of renal allograft function. Internet J Epidemiol 2003; 1.
23. Venables W, Ripley B. Modern Applied Statistics with S-Plus. New York: Springer, 2002.
24. Bateman AC, Al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1. Histopathology 1997; 30: 49-56.
25. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997; 41: 1757-61.
26. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998, 32: 209-16.
27. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998, 11: 929-33.
28. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002, 55: 662-8.
29. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001; 25: 158-61.
30. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003; 27: 150-8.
31. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006; 19: 417-28.
32. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24: 598-606.
33. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004, 35: 697-710.
34. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986; 123: 212-9.
35. Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms: An immunohistologic study of 400 cases. Am J Surg Pathol 1986, 10: 227-36.
36. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001; 25: 610-7.
37. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989; 13: 276-91.
38. Wick MR, Loy T, Mills SE, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990; 21: 759-66.
39. Ordonez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol 2006; 19: 373-83.
40. Battifora H. The Pleura. New York: Raven Press, 1989; 829-55.
41. DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol 1992; 36: 329-32.
42. Ordonez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998; 29: 166-9.
43. Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998; 109: 85-9.
44. Miettinen O. Theoretical Epidemiology. Principles of Occurrence Research in Medicine. New York: Wiley, 1985.
45. Greenland S. Summarization, smoothing, and inference in epidemiologic analysis. Scand J Soc Med 1993; 21: 227-31.
46. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002; 33: 953-67.
47. Ordonez NG. Value of cytokertin5/6 in distinguishing epithelial mesothelioma of pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22: 1215-21.
48. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998, 22: 1203-14.
49. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140-3.
50. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002; 40: 237-44.
51. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001; 125: 1316-20.
52. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-7.
53. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199: 479-87.
54. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146: 344-56.
55. Renshaw AA, Pinkus GS, Gorson JM. HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast. Mod Pathol 1995; 8: 152A.
56. Gonzalez-Lois C, Ballestin C, Sotelo MT, Lopez-Rios F, Garcia-Prats MD, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001; 38: 528-34.
57. Attanoos RL, Goddard H, Thomas ND, Jasani B, Gibbs AR. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995; 27: 361-6.
58. Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999, 112: 75-89.
59. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology 1994; 25: 431-7.
60. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986; 122: 252-60.
61. y in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989; 135: 931-8.
62. Hammar SP, Henderson DW, Klebe S, Dodson RF. Neoplasms of the pleura. In: Tomashefski JFJ, editor. Dail and Hammar's Pulmonary Pathology. 3rd ed. New York: Springer, 2008; Chapter 43.